Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States
Sean K McFarland
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States
Laura M Mateyka
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States; Biochemistry Center (BZH), Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States; Program in Biological and Medical Sciences, Harvard Medical School, Boston, United States
Jacob C Ulirsch
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States; Program in Biological and Medical Sciences, Harvard Medical School, Boston, United States
Leif S Ludwig
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States
Gaurav Agarwal
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States; University of Oxford, Oxford, United Kingdom; Harvard Stem Cell Institute, Cambridge, United States
Broad Institute of MIT and Harvard, Cambridge, United States
Jaroslaw P Maciejewski
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
Benjamin L Ebert
Broad Institute of MIT and Harvard, Cambridge, United States; Division of Hematology, Brigham and Women’s Hospital, Boston, United States; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States; Howard Hughes Medical Institute, Chevy Chase, United States
David E Root
Broad Institute of MIT and Harvard, Cambridge, United States
Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, United States; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States; Broad Institute of MIT and Harvard, Cambridge, United States; Harvard Stem Cell Institute, Cambridge, United States
Genome-wide association studies (GWAS) have identified thousands of variants associated with human diseases and traits. However, the majority of GWAS-implicated variants are in non-coding regions of the genome and require in depth follow-up to identify target genes and decipher biological mechanisms. Here, rather than focusing on causal variants, we have undertaken a pooled loss-of-function screen in primary hematopoietic cells to interrogate 389 candidate genes contained in 75 loci associated with red blood cell traits. Using this approach, we identify 77 genes at 38 GWAS loci, with most loci harboring 1–2 candidate genes. Importantly, the hit set was strongly enriched for genes validated through orthogonal genetic approaches. Genes identified by this approach are enriched in specific and relevant biological pathways, allowing regulators of human erythropoiesis and modifiers of blood diseases to be defined. More generally, this functional screen provides a paradigm for gene-centric follow up of GWAS for a variety of human diseases and traits.